EMAIL THIS PAGE TO A FRIEND

Autophagy

Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease.


PMID 25758767

Abstract

Mitochondria-induced oxidative stress and flawed autophagy are common features of neurodegenerative and lysosomal storage diseases (LSDs). Although defective autophagy is particularly prominent in Pompe disease, mitochondrial function has escaped examination in this typical LSD. We have found multiple mitochondrial defects in mouse and human models of Pompe disease, a life-threatening cardiac and skeletal muscle myopathy: a profound dysregulation of Ca(2+) homeostasis, mitochondrial Ca(2+) overload, an increase in reactive oxygen species, a decrease in mitochondrial membrane potential, an increase in caspase-independent apoptosis, as well as a decreased oxygen consumption and ATP production of mitochondria. In addition, gene expression studies revealed a striking upregulation of the β 1 subunit of L-type Ca(2+) channel in Pompe muscle cells. This study provides strong evidence that disturbance of Ca(2+) homeostasis and mitochondrial abnormalities in Pompe disease represent early changes in a complex pathogenetic cascade leading from a deficiency of a single lysosomal enzyme to severe and hard-to-treat autophagic myopathy. Remarkably, L-type Ca(2+)channel blockers, commonly used to treat other maladies, reversed these defects, indicating that a similar approach can be beneficial to the plethora of lysosomal and neurodegenerative disorders.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

V4629
(±)-Verapamil hydrochloride, ≥99% (titration), powder
C27H38N2O4 · HCl
PHR1131
(±)-Verapamil hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
C27H38N2O4 · HCl
D8375
2-Deoxy-D-glucose, ≥98% (GC), crystalline
C6H12O5
D6134
2-Deoxy-D-glucose, ≥99% (GC), crystalline
C6H12O5
D3179
2-Deoxy-D-glucose, BioXtra, ≥98%
C6H12O5
32883
4-tert-Octylphenol monoethoxylate solution, 1 μg/mL in acetone, analytical standard
C16H26O2
32882
4-tert-Octylphenol monoethoxylate solution, 10 μg/mL in acetone, analytical standard
C16H26O2
46940
6-[Fluorescein-5(6)-carboxamido]hexanoic acid N-hydroxysuccinimide ester, suitable for fluorescence, ≥75% (HPLC)
C31H26N2O10
A2754
Adenosine 5′-diphosphate sodium salt, bacterial, ≥95% (HPLC)
C10H15N5O10P2
L8918
Anti-LC3 antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
B1793
Bafilomycin A1 from Streptomyces griseus, ≥90% (HPLC)
C35H58O9
A6003
Bovine Serum Albumin, lyophilized powder, essentially fatty acid free, ≥96% (agarose gel electrophoresis)
M9546
D-Mannitol, BioXtra, ≥98% (GC)
C6H14O6
M9647
D-Mannitol, ACS reagent
C6H14O6
M4125
D-Mannitol, ≥98%
C6H14O6
M1902
D-Mannitol, plant cell culture tested
C6H14O6
M8429
D-Mannitol, meets EP, FCC, USP testing specifications
C6H14O6
63559
D-Mannitol, BioUltra, ≥99.0% (sum of enantiomers, HPLC)
C6H14O6
63560
D-Mannitol, ACS reagent, for microbiology, ≥99.0%
C6H14O6
17311
D-Mannitol, tested according to Ph.Eur.
C6H14O6
78513
D-Mannitol, ≥99.9999% (metals basis), for boron determination
C6H14O6
SRP3027 EGF human, Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), cell culture tested
11376454001 Epidermal Growth Factor, human (hEGF), recombinant (E. coli)
E5036
Epidermal Growth Factor, human, animal component free, EGF, recombinant, expressed in Escherichia coli, >97% (SDS-PAGE)
03777
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid, BioUltra, for molecular biology, ≥99.0% (T)
C14H24N2O10
03609
Ethylenediaminetetraacetic acid, BioUltra, ≥99.0% (KT)
C10H16N2O8
03620
Ethylenediaminetetraacetic acid, ≥98.0% (KT)
C10H16N2O8
03690
Ethylenediaminetetraacetic acid solution, BioUltra, for molecular biology, pH 8.0, ~0.5 M in H2O
C10H16N2O8
SRP3052
HB-EGF human, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC), cell culture tested
E9644
hEGF, EGF, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture